Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Key to changes
?
Text removedfrom 2022 Q1- Text added to 2022 Q2
Content analysis
?Positive | |
Negative | |
Uncertain | |
Constraining | |
Legalese | |
Litigous | |
Readability |
H.S. sophomore Avg
|
Content analysis
?Positive | |
Negative | |
Uncertain | |
Constraining | |
Legalese | |
Litigous | |
Readability |
H.S. sophomore Avg
|
New words:
American, AMKD, Antitrust, atrophy, autotemcel, Breakthrough, Catalyst, CB, concentrated, Conference, covenant, decision, degeneration, degrader, dry, EMA, exagamglogene, explanation, Fee, forum, glycemic, inaxaplin, insulin, Kingdom, knowledge, macular, moderate, package, PDUFA, PEG, PRIME, protease, resumed, scheduled, scope, SOFR, submission, track, undrawn, User, vast, Verve, viability, ViaCyte, waiting
Removed:
augment, enhance, function, KAFTRIOTM, licensed, pending, presenting, trademark
Valuein 2022 Q1 filing- Value in 2022 Q2 filing
Original filings
Filing view